|193.02||-23.75||-10.96%||Vol 13.70M||1Y Perf -26.54%|
|Jun 11th, 2021 16:00 DELAYED|
|- -||0.78 0.40%|
|Target Price||272.61||Analyst Rating||Strong Buy 1.40|
|Potential %||41.23||Finscreener Ranking||★★★★★ 60.44|
|Insiders Trans % 3/6/12 mo.||-100/-100/-97||Value Ranking||★★★★★ 61.85|
|Insiders Value % 3/6/12 mo.||-100/-100/-87||Growth Ranking||★★★★★ 81.02|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-86||Income Ranking||— -|
|Market Cap||49.97B||Earnings Rating||Sell|
|Price Range Ratio 52W %||0.12||Earnings Date||29th Jul 2021|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||29th Jul 2021|
|Estimated EPS Next Report||2.29|
|EPS Growth Next 5 Years %||11.90|
|Avg. Weekly Volume||4.08M|
|Avg. Monthly Volume||2.16M|
|Avg. Quarterly Volume||1.77M|
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) stock closed at 193.02 per share at the end of the most recent trading day (a -10.96% change compared to the prior day closing price) with a volume of 13.72M shares and market capitalization of 49.97B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 3400 people. Vertex Pharmaceuticals Incorporated CEO is Reshma Kewalramani.
The one-year performance of Vertex Pharmaceuticals Incorporated stock is -26.54%, while year-to-date (YTD) performance is -18.33%. VRTX stock has a five-year performance of 110.97%. Its 52-week range is between 192.88 and 306.08, which gives VRTX stock a 52-week price range ratio of 0.12%
Vertex Pharmaceuticals Incorporated currently has a PE ratio of 20.00, a price-to-book (PB) ratio of 6.05, a price-to-sale (PS) ratio of 8.44, a price to cashflow ratio of 16.40, a PEG ratio of 2.32, a ROA of 25.60%, a ROC of 33.22% and a ROE of 34.84%. The company’s profit margin is 43.16%, its EBITDA margin is 53.80%, and its revenue ttm is $6.41 Billion , which makes it $24.78 revenue per share.
Of the last four earnings reports from Vertex Pharmaceuticals Incorporated, there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $2.29 for the next earnings report. Vertex Pharmaceuticals Incorporated’s next earnings report date is 29th Jul 2021.
The consensus rating of Wall Street analysts for Vertex Pharmaceuticals Incorporated is Strong Buy (1.4), with a target price of $272.61, which is +41.23% compared to the current price. The earnings rating for Vertex Pharmaceuticals Incorporated stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Vertex Pharmaceuticals Incorporated has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Vertex Pharmaceuticals Incorporated has a Sell technical analysis rating based on Technical Indicators (ADX : 6.76, ATR14 : 5.54, CCI20 : -318.54, Chaikin Money Flow : -0.31, MACD : -2.00, Money Flow Index : 34.68, ROC : -7.54, RSI : 28.90, STOCH (14,3) : 0.57, STOCH RSI : 0.00, UO : 31.28, Williams %R : -99.43), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Vertex Pharmaceuticals Incorporated in the last 12-months were: Amit K. Sachdev (Option Excercise at a value of $167 935), Amit K. Sachdev (Sold 19 296 shares of value $4 216 614 ), Bastiano Sanna (Sold 4 444 shares of value $949 980 ), Bruce I. Sachs (Buy at a value of $3 260 464), Charles F. Wagner (Sold 700 shares of value $205 206 ), David Altshuler (Option Excercise at a value of $201 592), David Altshuler (Sold 18 545 shares of value $4 081 384 ), Jeffrey M Leiden (Sold 65 584 shares of value $18 766 603 ), Joy Liu (Sold 3 793 shares of value $793 209 ), Michael Parini (Option Excercise at a value of $796 641), Michael Parini (Sold 23 086 shares of value $5 192 713 ), Paul M. Silva (Option Excercise at a value of $295 288), Paul M. Silva (Sold 9 811 shares of value $2 293 904 ), Sangeeta N. Bhatia (Option Excercise at a value of $1 105 789), Sangeeta N. Bhatia (Sold 10 516 shares of value $2 805 518 ), Stuart A. Arbuckle (Option Excercise at a value of $1 021 039), Stuart A. Arbuckle (Sold 42 673 shares of value $9 394 299 )
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.